Loss of p120ctn causes EGFR-targeted therapy resistance and failure

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Epidermal growth factor receptor (EGFR) is crucial for cell division and survival, and its activation in cancer correlates with poor outcomes.
• Targeted EGFR therapy shows initial efficacy but often fails due to resistance mechanisms, highlighting an unmet clinical need.
• p120-catenin (p120ctn) is implicated as a biomarker for EGFR therapy, with its loss potentially inducing cancer and promoting invasiveness.

Purpose of the Study:

• To investigate if reduced p120-catenin expression contributes to resistance against EGFR-targeted therapies.
• To explore the role of p120ctn in the context of EGFR overexpression and therapeutic response.

Main Methods:

• Utilized human esophageal keratinocytes for experimental models.
• Administered EGFR-targeting compounds to cells with varying levels of EGFR and p120ctn expression.

Main Results:

• EGFR-targeting compounds effectively reduced cell viability in cells overexpressing EGFR.
• These therapies failed to induce toxicity in cells with both EGFR overexpression and decreased p120ctn expression.
• Data indicate that reduced p120ctn expression confers resistance to EGFR-targeted therapy.

Conclusions:

• Decreased p120ctn expression is a key mechanism driving resistance to EGFR-targeted therapies.
• These findings are vital for developing strategies to overcome therapeutic resistance in EGFR-driven cancers.